On May 28, 2026 Onc.AI, a digital health company developing computational biomarkers and decision-support products in oncology using Deep Learning imaging AI, reported positive external validation results for Onclara IO, an imaging-based AI biomarker that stratifies survival outcomes in patients with PD-L1-High, mutation negative metastatic non-small cell lung cancer (mNSCLC) receiving first-line immune checkpoint inhibitor (ICI) monotherapy. The findings will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting in Chicago. In an external blinded validation conducted on a Flatiron Health longitudinal imaging dataset, Onclara IO derived from a single pretreatment CT scan, the patients most likely to benefit from ICI monotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared to 155 days for Onclara IO Low patients. "These results position Onclara IO as a noninvasive imaging biomarker that complements PD-L1 testing, with the potential to inform first-line treatment selection and risk-adapted strategies in this population," said Ravi Parikh, MD, first author on this work and Medical Director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute, Emory University.

"As longstanding partners of Onc.AI, we are pleased to see Flatiron’s high-quality, real-world data support the independent validation of Onclara IO in patients with PD-L1-high metastatic non-small cell lung cancer. These findings reinforce the value of combining curated real-world data with imaging AI to advance more precise, biomarker-informed treatment decisions, and we look forward to continuing this collaboration as Onc.AI achieves additional milestones together," said Jacqueline Law, Ph.D., VP, Scientific Engagement and Applied Research at Flatiron Health.

Onclara IO is not FDA cleared and is not available for commercial use. Onc.AI expects to submit Onclara IO for clearance as a software-as-medical-device in 2027.

(Press release, Onc AI, MAY 28, 2026, View Source [SID1234666172])

On May 28, 2026 Ontada, a McKesson business dedicated to real-world oncology data and insights, will present a real-world observational research study in an oral presentation at the American Society of Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting examining GLP-1 receptor agonist (RA) utilization and overall survival outcomes among patients treated in U.S. community oncology practices.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, titled, "GLP 1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort," analyzed patients diagnosed with cancer between January 2021 and October 2024, with follow-up through October 2025. Investigators identified 418 patients treated with a GLP-1 receptor agonist and 3,476 non-users, with matching by cancer type and diagnosis year to evaluate overall survival (OS) outcomes.

Key Data Findings

Propensity-score adjusted Cox proportional hazards models evaluated the association between GLP1 RA use and overall survival among patients diagnosed with breast, prostate, colorectal, lung, hepatocellular or renal cancer. After adjustment for confounders including age, BMI, cancer stage and type, GLP‑1 receptor agonist use was significantly associated with improved overall survival (hazard ratio 0.66; 95% CI 0.45–0.97; p = 0.0031).

"While GLP-1 therapies are well established for metabolic disease, emerging preclinical and observational data suggest potential anticancer effects, yet large-scale studies investigating this association have been limited," said Jess Paulus, ScD, vice president of Real-World Research at Ontada and presenting author of the study. "As use of these therapies continues to expand, high-quality real-world data are essential to understanding their broader impact. Our findings demonstrate the value of real-world evidence in identifying anticancer signals and helping efficiently guide future research and prioritization of prospective studies."

Study Methodology

This retrospective analysis used data collected between January 2021 and October 2024, with follow‑up through October 2025, and evaluated GLP‑1 receptor agonist use, including dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Overall survival was measured from initial cancer diagnosis to death from any cause, with methods applied to address immortal time bias. Among patients who received a GLP‑1 receptor agonist, median age was 63 years, 58% were White, and 57% had a body mass index (BMI) ≥30 kg/m². Semaglutide accounted for the majority of prescriptions (55%). By comparison, non‑users had a median age of 68 years, 58% were White, and 28% had BMI ≥30 kg/m². Most GLP‑1 users (74%) initiated therapy after initial cancer diagnosis, of whom 7% initiated after a metastatic diagnosis, with breast (27%) and prostate (13%) cancers representing the most common malignancies among this group.

"At Ontada, our focus is on advancing cancer care by transforming real-world data into meaningful insights," said Christine Davis, president, Ontada. "This research reflects Ontada’s commitment to generating high-quality, real-world evidence that helps advance how cancer is understood and treated. By studying emerging therapies within community oncology settings, we can help surface insights that inform future research and ultimately support better outcomes for patients."

Other Research & Activities at ASCO (Free ASCO Whitepaper) 2026

Ontada is a part of McKesson, which has a broad portfolio of oncology and multispecialty solutions and partners that provide research, insights, technologies and services that help to address barriers and improve cancer and multispecialty care. At ASCO (Free ASCO Whitepaper), McKesson-supported businesses including The US Oncology Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 171 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies and early-phase studies.

For a comprehensive list of Ontada’s 14 accepted abstracts, visit Ontada’s ASCO (Free ASCO Whitepaper) 2026 site. Additionally, visit the Ontada Booth (#30123) at the McCormick Place Convention Center from May 29 – June 2 to explore the data presented at ASCO (Free ASCO Whitepaper) and discuss Ontada’s solutions.

Expert Panel on Community Oncology During ASCO (Free ASCO Whitepaper) 2026

Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 3, 2026, at 12 p.m. ET, titled, "Delivering Excellence, Close to Home." Panelists include Jason Hammonds, president of Oncology & Multispecialty for McKesson, John Schuler MD, medical director and radiation oncologist with Compass Oncology, and Dr. Patt. Register and join the panelists as they share their insights and perspectives on what is working today—and what needs to evolve—to support and strengthen community oncology as a foundational component of the cancer care ecosystem.

(Press release, McKesson, MAY 28, 2026, View Source [SID1234666171])

On May 28, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key data that will be presented include:

Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations.
Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases.
Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval.
"Our presence at this year’s ASCO (Free ASCO Whitepaper) reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum."

Key Guardant Health and collaborator presentations at ASCO (Free ASCO Whitepaper) 2026

Presentation

Title

Time / Location

8502

Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study

May 29, 2026 / 1:00 – 4:00 PM CDT

3525 / 279

A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance)

May 30, 2026 / 9:00 AM – 12:00 PM CDT

3546 / 313

A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS)

May 30, 2026 / 9:00 AM – 12:00 PM CDT

3572 / 339

Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer

May 30, 2026 / 9:00 AM – 12:00 PM CDT

3659 / 426

Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD)

May 30, 2026 / 9:00 AM – 12:00 PM CDT

4050 / 33

Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)

May 30, 2026 / 9:00 AM – 12:00 PM CDT

4159 / 142

First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis

May 30, 2026 / 9:00 AM – 12:00 PM CDT

4161 / 144

Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP

May 30, 2026 / 9:00 AM – 12:00 PM CDT

4238 / 221

Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy

May 30, 2026 / 9:00 AM – 12:00 PM CDT

3051 / 188

Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME)

May 30, 2026 / 1:30 – 4:30 PM CDT

3052 / 189

Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study

May 30, 2026 / 1:30 – 4:30 PM CDT

3070 / 207

Cell-free DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients

May 30, 2026 / 1:30 – 4:30 PM CDT

3077 / 214

Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling

May 30, 2026 / 1:30 – 4:30 PM CDT

3105 / 242

Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M)

May 30, 2026 / 1:30 – 4:30 PM CDT

1031 / 145

Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer

June 1, 2026 / 1:30 – 4:30 PM CDT

1095 / 209

Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i)

June 1, 2026 / 1:30 – 4:30 PM CDT

The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO (Free ASCO Whitepaper) 2026 can be found on the ASCO (Free ASCO Whitepaper) website.

About Guardant360 Liquid CDx

The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives.

About Guardant360 Liquid

Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.

About Guardant Reveal

Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.

The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.

About Shield

Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.

(Press release, Guardant Health, MAY 28, 2026, View Source [SID1234666170])

On May 28, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. Next establishes a new category of "real-time clinical intelligence" — a departure from legacy retrospective analyses and generic EHR alerts — designed to facilitate the delivery of precision medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To demonstrate the real-world impact of these expanded capabilities, Tempus will showcase a landmark study at ASCO (Free ASCO Whitepaper) 2026, describing clinically meaningful improvements in rates of biomarker testing for early-stage non-small cell lung cancer (eNSCLC) after the implementation of Tempus Next. The multi-center prospective study evaluated the deployment of the Tempus Next AI-enabled clinical decision support system (AI-CDSS) across 662 eNSCLC patients at six diverse U.S. community health systems.

The Next platform drove significant behavioral change and successfully closed critical care gaps by analyzing unstructured EHR data to identify patients who did not receive guideline-directed biomarker testing. Key findings from the study include:

The implementation of real-time interventions delivered an absolute testing rate lift of +24% for ALK, +18% for EGFR, and +13% for PD-L1 within 90 days of pathologic diagnosis.
The program translated testing directly into optimized therapy management, with 89% of treated patients receiving guideline-concordant therapy.
The expanded platform will surface insights from patients across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers. Furthermore, Next has introduced a suite of advanced intelligence capabilities that enable precision medicine teams to map patient experiences and develop targeted care gap programs that support their institution’s health equity initiatives.

"The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey," said Ryan Fukushima, CEO of Data and Apps at Tempus. "By expanding Next, we are providing our health systems partners with a 360-degree view to not only identify these gaps but to quantify the truly addressable opportunities for intervention. Our goal is to ensure that clinical innovation reaches every patient, closing the gap between the latest biomarker-driven therapies and community-level care to improve outcomes at scale."

(Press release, Tempus, MAY 28, 2026, View Source [SID1234666169])

On May 28, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that nine abstracts have been accepted at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), scheduled to take place May 30 – June 2, 2026, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth #33137.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstracts underscore the broad clinical utility of BostonGene’s AI-powered models and advanced analytical platforms, including the Tumor Portrait test and Kassandra cell deconvolution. Spanning both tissue and peripheral blood analysis, the featured research showcases how integrating deep genomic, transcriptomic, and immunomic profiling can identify novel actionable biomarkers, predict immunotherapy response and toxicity, and map complex resistance mechanisms. Developed in collaboration with leading institutions such as the UT MD Anderson Cancer Center, Weill Cornell Medicine, and the Parker Institute for Cancer Immunotherapy, these studies highlight BostonGene’s pivotal role in accelerating biomarker discovery and optimizing patient stratification for clinical trials.

Details about the abstracts selected for presentation can be found below:

Poster presentations
Poster number: 273
Title: TROP2 as an actionable biomarker for anal cancer
Date & time: May 30 | 9:00 AM – 12:00 PM
Speaker: Mir Lim, MD, UT MD Anderson

BostonGene and MD Anderson Cancer Center collaborated to perform comprehensive genomic profiling of localized and metastatic anal cancers, assessing TACSTD2 (TROP2) expression as a potential therapeutic biomarker. The analysis found high TACSTD2 expression that correlated with TROP2 immunohistochemistry, supporting its potential use in identifying patients who may benefit from anti-TROP2 antibody-drug conjugates. The study underscores the clinical utility of BostonGene’s Tumor Portrait test in biomarker discovery and validation.

Research conducted in collaboration with UT MD Anderson

Poster number: 257
Title: Developing harmonized tumor microenvironment subtypes for patient stratification in clinical trials
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Sofya Kust, PhD, BostonGene

BostonGene developed an AI-driven harmonized tumor microenvironment (HTME) classification system to improve patient stratification for immunotherapy and targeted therapies across solid tumors. By applying machine learning approaches—including agglomerative clustering, K-nearest neighbors classification, and transcriptomic pathway analysis—to RNA-seq data from more than 40,000 cancer samples, the study identified nine reproducible TME subtypes capturing key biological features such as immune activity, fibrosis, vascularization, and hypoxia. The AI-based framework outperformed existing methods by integrating multiple biological dimensions simultaneously and accurately predicting treatment response and progression-free survival across different cancer types and therapies.

Poster number: 323
Title: Multimodal immunoprofiling of peripheral blood using foundation models of the immune system for predicting immunotherapy response and toxicity in the RADIOHEAD pan-cancer cohort
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Evgeny Barykin, PhD, BostonGene

In collaboration with Parker Institute for Cancer Immunotherapy, BostonGene applied AI-based models of the immune system to analyze blood samples from more than 1,000 cancer patients receiving immune checkpoint inhibitor (ICI) therapy in the RADIOHEAD pan-cancer cohort. By combining RNA sequencing, flow cytometry, and machine learning models trained on 45,000 patient profiles, the study identified immune signatures linked to both treatment response and severe immune-related toxicities. The AI-driven embeddings and multimodal immunoprofiling approach successfully stratified patients into responder, non-responder, and high-risk toxicity groups, highlighting the potential of AI-powered peripheral blood profiling to improve immunotherapy patient selection.

Research conducted in collaboration with Parker Institute for Cancer Immunotherapy

Poster number: 360
Title: Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq–based prediction of severe adverse event risk and rheumatoid arthritis
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Alexander Bagaev, PhD, BostonGene

BostonGene utilized its immune model leveraging multimodal TCR/BCR repertoire data to address two critical clinical challenges: predicting severe immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors and detecting rheumatoid arthritis from peripheral blood. By integrating adaptive immune receptor repertoire embeddings with gene expression signatures, the model significantly outperformed traditional immune repertoire analysis approaches—such as clonality, diversity, and V(D)J gene usage metrics—in both predictive accuracy and cross-cohort robustness. These advances enabled earlier risk stratification and more precise immunotherapy management than conventional biomarker methods.

Poster number: 533
Title: Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CART cell therapy
Date & time: June 1 | 9:00 AM – 12:00 PM
Speaker: Samuel Yamshon, MD, Weill Cornell Medicine

BostonGene applied its multimodal molecular profiling platform to characterize the systemic immune remodeling driven by tazemetostat priming in patients with B-cell lymphomas receiving CART therapy. By integrating high-parameter flow cytometry, RNA sequencing, immune cell deconvolution, and functional gene signature analysis, BostonGene’s analysis revealed systemic immune remodeling associated with enhanced antigen presentation, T-cell activation, and reduced immunosuppressive signaling—supporting the use of EZH2 inhibition for improved CART efficacy and durability.

Research conducted in collaboration with Weill Cornell Medicine

Poster number: 268b
Title: IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)-positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC)
Date & time: June 1 | 1:30 PM – 4:30 PM
Speaker: Jason Mouabbi, MD, UT MD Anderson

In a trial in progress with UT MD Anderson Cancer Center, BostonGene will perform multimodal longitudinal blood and tissue analysis for mILC patients receiving the bispecific antibody targeting PD-1 and VEGF, ivonescimab. Moving beyond traditional efficacy metrics, complex correlates linking clinical outcomes with molecular features are ongoing. By integrating real-time ctDNA dynamics with predictive responder scores, BostonGene aims to identify critical markers of response and resistance needed to optimize treatment durability and refine future trial strategies.

Research conducted in collaboration with UT MD Anderson

Online only
Abstract number: e12594
Title: Examining the tumor microbiology and microenvironment of patients with triple negative inflammatory breast cancer receiving Keynote 522

Stage III triple‑negative inflammatory breast cancer patients receiving KN522 therapy were analyzed with BostonGene’s integrative multimodal platform. By combining intrinsic subtype classification with immune deconvolution, BostonGene successfully mapped the molecular landscape of treatment response. Non-responders were marked by angiogenic and endothelial remodeling and potential biomarkers of brain metastasis risk, demonstrating the platform’s unique capability to predict both therapeutic outcomes and disease progression.

Research conducted in collaboration with UT MD Anderson

Abstract number: e13080
Title: Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC)
Description: Clinicians at MD Anderson Cancer Center utilized BostonGene’s Tumor Portrait test to validate the impact of comprehensive genomic profiling in guiding treatment decisions and predicting outcomes in a heterogeneous real-world mBC cohort. The findings demonstrated that BostonGene’s integrated approach uncovered clinically actionable insights and predictive signatures that directly guided treatment selection and improved patient outcomes.

Research conducted in collaboration with UT MD Anderson

Abstract number: e16004
Title: Association of angiogenic, fibrotic, and immunosuppressive tumor microenvironment with immunotherapy outcomes in metabolic disease–associated biliary tract cancers

Researchers at MD Anderson Cancer Center leveraged BostonGene’s transcriptomic classifiers and KassandraTM cell deconvolution to characterize the tumor microenvironment (TME) of metabolic disease-associated biliary tract cancers. The analysis uncovered a distinct TME in metabolic disease-associated cholangiocarcinoma that likely impairs response to immune checkpoint inhibitors, demonstrating the value of BostonGene’s AI-powered solutions for therapeutic response prediction and trial design.

Research conducted in collaboration with UT MD Anderson

For more information, please visit the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings.

(Press release, BostonGene, MAY 28, 2026, View Source [SID1234666168])